Cited by 39Regulation of Appetite and ObesityPituitary Gland Disorders and TreatmentsThyroid Disorders and Treatments

Triiodothyronine supplementation for hypothalamic obesity

Fernandes, J.K., Klein, M.J., Ater, Joann L., Kuttesch, John F., Vassilopoulou-Sellin, Rena·2002·Metabolism

Abstract

Patients with suprasellar lesions develop profound hypothalamic obesity and listlessness with no effective treatment. We added triiodothyronine (T(3)) supplementation in 3 such patients and present their response. All had previous nutritional counseling without benefit. All were treated for diabetes insipidus (DI) and hypopituitarism; serum free thyroxine (T(4)) level was normal. A 24-year-old woman (pineal tumor and astrocytoma) had weight gain (4.7 kg/yr for 3 years), cold intolerance, fatigue, dry skin, and constipation; after T(3), she lost 14 kg over 27 months and reported overall improvement. Her bone mineral density also improved. A 10.6-year-old boy (optic glioma) was gaining 6 kg/yr for 4 years; after T(3) supplement, he lost 4.3 kg over 11 months. A 12-year-old girl (mixed germ cell tumor) had weight gain (8.3 kg/yr for 3 years) and listlessness; after T(3), she lost 8.1 kg over 16 months and had improved alertness. All patients were asymptomatic despite supraphysiologic T(3) levels. We suggest that T(3) may serve as a simple and effective supplement, which can promote weight loss and improve the well being of these patients with hypothalamic obesity.

Integrity signals

Registry

Crossref · 10.1053/meta.2002.35591

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • One small case series appeared to demonstrate a benefit of T3 supplementation for weight loss.

    “One small case series appeared to demonstrate a benefit of T3 supplementation for weight loss (23)”

    From Approach to the patient with acquired hypothalamic syndrome (2026) · cites this paper as [23]

Cited by

Sorted by citations

Authors
Fernandes, J. K., Klein, M. J., Ater, J. L., Kuttesch, J. F., & Vassilopoulou-Sellin, R.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Venue
Metabolism
Publisher
Elsevier BV
Published
2002-11
Volume
51
Issue
11
Pages
1381-1383
ISSN
0026-0495 (ISSN-L)
OpenAlex
W2007932205
Cited by
39
References
0
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 1 · 2015: 2 · 2014: 3 · 2013: 2 · 2012: 1
FWCI
0.21
Type
journal article
Language
en
Open access
closed
Locations
  • Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
Keywords
hypothalamic obesity, suprasellar lesions, weight loss, pineal region tumors, optic nerve glioma, germ cell tumors, bone mineral density, listlessness, hypopituitarism, diabetes insipidus
MeSH terms
Adult, Brain Neoplasms, Child, Female, Humans, Hypothalamic Diseases, Male, Obesity, Triiodothyronine, Weight Loss, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review